Enclomiphene contraindications: who should not take it

Last updated 2026-07-27

What is enclomiphene and how is it different from clomiphene?

Enclomiphene is one of the two isomers that make up clomiphene citrate, the older fertility drug most people know as Clomid. Clomiphene is actually a mix of two mirror-image molecules, enclomiphene and zuclomiphene, in roughly a 62:38 ratio ^[1]. Enclomiphene is the isomer that does most of the useful work: it blocks estrogen receptors in the hypothalamus, which tricks the brain into thinking estrogen is low, which ramps up GnRH, then LH and FSH, then testosterone and sperm production, all from the man's own testicles. Zuclomiphene, the other isomer, sticks around in the body much longer (its half-life is estimated at roughly 30 days versus about 4 days for enclomiphene ^[1]) and doesn't do much for testosterone. Some researchers think it contributes more side effects than benefit. That's the whole pitch behind isolating enclomiphene on its own: same mechanism, theoretically less baggage. Here's the regulatory reality, though. Enclomiphene was studied for years under the name Androxal, developed by Repros Therapeutics, and it never got FDA approval as a standalone drug. The program stalled out after the FDA asked for more safety data on cardiovascular outcomes and vision effects, and Repros never completed the trials needed to get it across the finish line ^{[2] [3]}. What men buy today under the name enclomiphene is compounded medication, made by a compounding pharmacy under a doctor's prescription, not an FDA-approved manufactured drug pulled off a national supply chain. That distinction matters for contraindications too, because compounded product doesn't come with an FDA-reviewed label spelling out every warning. You're relying on the prescribing doctor's judgment and the clinical literature, not a package insert.

Who should not take enclomiphene? The core contraindications

A few groups should not take enclomiphene at all, based on how the drug works and what's known about clomiphene's safety profile (since enclomiphene shares clomiphene's mechanism and much of its side effect data). Men with significant liver disease. SERMs are metabolized through the liver, and the clomiphene label carries a hepatic impairment warning ^[4]. If your liver enzymes are already elevated or you have a diagnosed liver condition, this is not a drug to self-start. A history of blood clots (DVT, pulmonary embolism) or active thromboembolic disease. Estrogen-receptor-modulating drugs as a class have been linked to clotting risk, and clomiphene's label specifically warns against use in patients with thrombophlebitis or thromboembolic disorders ^[4]. Hormone-sensitive cancers, including a personal history of prostate cancer. Because enclomiphene raises testosterone and estradiol both go up as a downstream effect, oncologists are cautious here. Anyone with a history of prostate cancer needs a urology-cleared conversation before touching this drug, not a website checkout. Pituitary tumors, especially anything affecting the pituitary or hypothalamus. Enclomiphene works by leaning on that exact axis. A macroadenoma or other structural pituitary problem changes the entire risk calculus and needs imaging and endocrinology input first. Undiagnosed abnormal vision changes. Clomiphene's label includes warnings about visual disturbances, including blurred vision and scotomata (visual field defects), and states patients experiencing new vision symptoms should stop the drug and get an ophthalmologic exam ^[4]. Vision changes are uncommon but this is one of the few clomiphene side effects that shows up as a hard stop-and-call-your-doctor instruction. Women who are pregnant or could become pregnant. This one is absolute. Clomiphene is a pregnancy category X-type risk in its original indication and is not used in pregnant women; enclomiphene, sharing the same estrogen receptor mechanism, is not a drug for women trying to conceive or already pregnant.

Does enclomiphene work if you have primary testicular failure?

No, and this is one of the most common misunderstandings men bring to this drug. Enclomiphene raises testosterone by increasing LH and FSH signaling from the pituitary to the testicles. If the testicles themselves are the problem (primary hypogonadism, sometimes called primary testicular failure), the signal goes out but nothing responds. LH can already be elevated in these men because the pituitary is shouting louder to a testicle that can't answer. This is why a baseline LH and FSH panel matters before starting. If FSH and LH are already high and testosterone is low, that pattern points to primary testicular failure, and a SERM will not fix it. Enclomiphene is designed for secondary (hypothalamic-pituitary) hypogonadism, where the testicles are capable but the upstream signal is weak, often from age, obesity, opioid use, or other suppressive factors. A man with primary testicular failure who takes enclomiphene anyway is more than wasting money. He's delaying a proper workup and possibly missing a diagnosis (like Klinefelter syndrome, testicular injury, or prior chemotherapy exposure) that needs different management entirely.

Does enclomiphene actually preserve fertility better than TRT?

This is the real draw for a lot of men, and the mechanism does make biological sense, but the promise needs honest limits. Exogenous testosterone (injections, gels, pellets) shuts down the hypothalamic-pituitary-gonadal axis directly. The brain sees plenty of testosterone circulating, stops sending LH and FSH, and sperm production drops, sometimes to zero, sometimes for many months after stopping. Enclomiphene does the opposite: it stimulates the brain to send more LH and FSH, which is why testicular size and sperm production tend to hold up or improve, unlike on TRT. A 2023 randomized trial comparing enclomiphene to injectable testosterone in men with low testosterone found enclomiphene maintained sperm concentration and testicular volume while raising testosterone, whereas the testosterone group saw sperm counts and testicular volume drop significantly ^[5]. But 'tends to preserve fertility' is not the same as 'guarantees a pregnancy' or 'restores fertility in a man who already has abnormal semen parameters.' The clinical trial evidence is still limited in size and duration, most studies run months, not years, and there's no large-scale outcomes data proving live birth rates improve. If fertility is your primary goal, this is a conversation for a reproductive urologist with a semen analysis in hand, not an assumption based on mechanism alone.

What side effects should make you stop enclomiphene?

Most men tolerate enclomiphene reasonably well, but there are recognizable warning signs on clomiphene's safety data (which is the closest large dataset we have) worth knowing before you start. Visual disturbances: blurred vision, seeing spots, or light flashes. Stop and get evaluated; this is explicitly called out on the clomiphene label ^[4]. Signs of a blood clot: sudden leg swelling or pain, chest pain, shortness of breath. This needs emergency evaluation, not a wait-and-see approach. Mood changes: irritability and mood swings are commonly reported with SERMs, likely tied to fluctuating estradiol. Not usually dangerous, but worth flagging to your prescriber if it's affecting your life. Gynecomastia or breast tenderness: paradoxically possible even though the drug is anti-estrogenic at the hypothalamus, because it can be estrogenic in other tissues, and total estradiol often rises as testosterone rises and aromatizes. Headaches and mild GI upset: common and usually mild, not typically a reason to stop outright but worth mentioning at follow-up. None of this replaces bloodwork. Anyone on enclomiphene should have baseline labs (total and free testosterone, LH, FSH, estradiol, liver panel, lipid panel, CBC, and a PSA if age-appropriate) and a follow-up panel at roughly 6 to 8 weeks to see how the numbers actually moved, more than how the person feels.

Can you take enclomiphene with other medications?

There's no FDA-reviewed drug interaction list for enclomiphene specifically, because there's no FDA-approved label at all. What exists is inference from clomiphene's pharmacology and general SERM class knowledge, so this section deserves extra hedging. Other hormonal therapies (exogenous testosterone, anastrozole, hCG) are commonly combined or substituted in real prescribing practice, but combining enclomiphene with exogenous testosterone defeats much of its purpose, since you're back to suppressing the axis you're trying to stimulate. If a doctor adds an aromatase inhibitor like anastrozole, that's usually to manage estradiol that rose too far, not something to self-dose. Anticoagulants and a personal clotting history deserve specific caution given the class-wide thromboembolic warning already discussed. Liver-metabolized medications in general warrant a conversation with the prescribing doctor, simply because enclomiphene adds to hepatic load and there's limited compounded-product-specific interaction data published anywhere. The honest answer here is that a prescriber who actually reviews your full medication list, not a generic web chart, is the only reliable filter for interactions with a compounded, non-FDA-approved product.

Is enclomiphene legal, and is it FDA-approved?

Enclomiphene is legal to prescribe and dispense in the United States, but it is not FDA-approved as a standalone medication. The compound itself (as one isomer of clomiphene) has a research and regulatory history stretching back decades, and clomiphene citrate itself is FDA-approved, but only for ovulation induction in women ^[4], not for male hypogonadism and not as isolated enclomiphene. The Androxal development program, run by Repros Therapeutics, filed with the FDA multiple times between roughly 2010 and 2016 seeking approval for enclomiphene citrate as a testosterone-boosting treatment for men with secondary hypogonadism and obesity. The FDA repeatedly declined to approve it, citing insufficient long-term safety data, including concerns about cardiovascular risk and effects on the pituitary and vision over extended use ^{[2] [3]}. Repros eventually stopped pursuing the indication. Because there's no approved manufactured version, everything sold today under the enclomiphene name is compounded by a licensed compounding pharmacy, prepared under a valid prescription, typically under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding for an individual patient based on a prescriber's order . This is legal, but it means enclomiphene does not go through the FDA's premarket approval process that reviews efficacy and safety data before a drug reaches the market. Quality and dosing accuracy depend on the compounding pharmacy's own standards and any state board of pharmacy oversight, not an FDA manufacturing inspection specific to this drug.

How do you know if enclomiphene is right for you before starting?

The honest starting point is a full hormone panel, not a symptom checklist. At minimum that means total testosterone (ideally two morning draws, since levels vary and single readings can mislead), free testosterone, LH, FSH, estradiol, and a metabolic panel including liver enzymes. If LH and FSH come back low or inappropriately normal alongside low testosterone, that's the secondary hypogonadism pattern enclomiphene is meant to address. If LH and FSH are already elevated, that points toward primary testicular failure, and enclomiphene isn't the right tool (see the section above). Men actively trying to conceive should also get a baseline semen analysis before starting anything, so there's a real number to compare against later, rather than a vague sense of whether things got better or worse. Once labs support the secondary hypogonadism pattern and no contraindication applies, dosing itself is its own topic. For men who get a green light, Enclomiphene Direct dosage covers typical starting doses and titration, and the Enclomiphene Direct dosage calculator helps translate a prescribed dose into an actual reconstituted volume.

What does a provider-reviewed path look like in practice?

Because enclomiphene is compounded and not FDA-approved as a standalone drug, the two things that actually protect a patient are a prescriber who reviews labs and history properly, and a pharmacy that compounds to a real quality standard. Enclomiphene Direct's model connects men with independent, licensed prescribers who review bloodwork and medical history before anything ships, and the prescriptions are filled by a licensed compounding pharmacy partner, not manufactured or compounded by Enclomiphene Direct itself. That structure doesn't erase the contraindications covered in this article; a provider review exists specifically to catch them, flag a liver problem, an elevated FSH pattern, a clotting history, before a vial ever gets reconstituted. If you're cleared and starting for the first time, the practical next steps (reconstitution, injection technique, injection sites, and how long a typical cycle runs) are covered in how to reconstitute Enclomiphene Direct, Enclomiphene Direct how to inject, Enclomiphene Direct injection sites, and Enclomiphene Direct cycle length.

Frequently asked questions

Can women take enclomiphene?

No. Enclomiphene is studied and prescribed for male secondary hypogonadism. Women who are pregnant or could become pregnant should not take it; the parent compound clomiphene has a well-documented pregnancy contraindication, and enclomiphene shares its estrogen-receptor mechanism ^[5]. This is not a fertility drug for women in the way clomiphene itself sometimes is used.

Is enclomiphene safe for men with high blood pressure?

There's no absolute contraindication for hypertension alone, but cardiovascular risk factors deserve extra scrutiny given that the FDA cited cardiovascular safety concerns when it declined to approve the Androxal program ^[3]. Men with poorly controlled blood pressure, heart disease, or a clotting history need their prescriber to weigh that risk before starting, not skip it.

Does enclomiphene cause blood clots?

Clomiphene's FDA label warns against use in patients with a history of thrombophlebitis or thromboembolic disorders ^[5]. Enclomiphene shares clomiphene's estrogen-receptor mechanism, so the same caution applies. Sudden leg swelling, calf pain, chest pain, or shortness of breath while on enclomiphene needs emergency evaluation, not a wait-and-see approach.

Can you take enclomiphene if you've had prostate cancer?

This needs a urologist's clearance first. Enclomiphene raises testosterone, and a personal history of prostate cancer is treated as a serious relative contraindication across hormone therapies generally. There's no enclomiphene-specific outcomes data in men with a prostate cancer history, which is exactly why it needs specialist sign-off rather than a self-start.

What labs do you need before starting enclomiphene?

At minimum: total and free testosterone (two morning draws is ideal), LH, FSH, estradiol, a liver panel, lipid panel, CBC, and PSA if age-appropriate. LH and FSH matter most, because they distinguish secondary hypogonadism (where enclomiphene can help) from primary testicular failure (where it won't work at all).

Does enclomiphene affect vision?

Uncommonly, yes. Clomiphene's label lists visual disturbances, including blurred vision and scotomata (spots or gaps in the visual field), as a reason to stop the drug and get an ophthalmologic exam ^[5]. Because enclomiphene shares clomiphene's mechanism, the same warning is treated as applicable, even though isolated enclomiphene has less standalone long-term safety data.

Is enclomiphene the same as Clomid?

No, but they're related. Clomid (clomiphene citrate) is a mixture of two isomers, enclomiphene and zuclomiphene, in roughly a 62:38 ratio ^[1]. Enclomiphene is the isomer that does most of the testosterone-raising work; zuclomiphene has a much longer half-life (around 30 days versus about 4 days ^[2]) and is thought to contribute more side effects than benefit.

Is enclomiphene FDA-approved?

No. Enclomiphene as a standalone drug (developed as Androxal) never received FDA approval; the manufacturer's applications were turned down over insufficient long-term safety data ^[3][4]. What's sold today is compounded medication made by a licensed compounding pharmacy under an individual prescription, not an FDA-approved manufactured product.

Does enclomiphene preserve fertility better than TRT?

The mechanism and available trial data both point that direction: a 2023 randomized study found enclomiphene maintained sperm concentration and testicular volume while raising testosterone, while injectable testosterone significantly reduced both ^[6]. That's a real, mechanism-supported difference, but it's not the same as a guarantee of preserved or improved fertility for every man.

Who should not take enclomiphene?

Men with significant liver disease, a history of blood clots or thromboembolic disease, hormone-sensitive cancers (including prior prostate cancer without clearance), pituitary tumors, or primary testicular failure should not take enclomiphene without specialist input. Women who are or could become pregnant should not take it at all.

Can enclomiphene cause gynecomastia?

It's possible, though less common than with anabolic steroid use. As testosterone rises on enclomiphene, some of it aromatizes into estradiol, and estradiol can rise enough in some men to cause breast tenderness or gland growth. Follow-up estradiol labs and reporting new breast symptoms to the prescriber let this get caught and managed early.

How long does it take enclomiphene to raise testosterone?

Most protocols check labs around 6 to 8 weeks after starting, since that's roughly when testosterone, LH, and FSH levels stabilize enough to judge a response. Individual timelines vary based on baseline hormone levels, body weight, and dose, which is one reason follow-up bloodwork matters more than how a person feels day to day.

Sources

1. PubMed / clinical pharmacology review, clomiphene isomer ratio: Clomiphene citrate is a mixture of enclomiphene and zuclomiphene in roughly a 62:38 ratio
2. FDA, Endocrinologic and Metabolic Drugs Advisory Committee materials on Androxal (enclomiphene citrate): FDA reviewed enclomiphene citrate (Androxal) for male secondary hypogonadism and raised safety data concerns
3. U.S. Securities and Exchange Commission, Repros Therapeutics annual report disclosures: Repros Therapeutics' Androxal (enclomiphene) program did not receive FDA approval after repeated review cycles
4. FDA-approved prescribing information for clomiphene citrate: Clomiphene citrate label warnings on hepatic impairment, thromboembolic disorders, pregnancy, and visual disturbances
5. Journal of Sexual Medicine, randomized trial of enclomiphene vs. testosterone therapy: Enclomiphene maintained sperm concentration and testicular volume while raising testosterone, versus significant declines in men on injectable testosterone